Introduction
Prostate cancer is the second cause of death from malignancies among Western men (Parker et al., 1997) . The molecular mechanisms involved in the progression of prostate cancer are poorly understood. The most frequent genetic alterations in prostate tumors are losses of heterozygosity (LOH) involving chromosome arms 7q, 8p, 10q, 13q, 16q, 17q, and 18q, pointing to the presence of tumor suppressor genes in these deleted regions (Carter et al., 1990; Bergerheim et al., 1991; Bova et al., 1993; Latil et al., 1994; Zenklusen et al., 1994; Gao et al., 1995; Cooney et al., 1996) . Chromosome arm 10q was one of the ®rst to be identi®ed as being aected by extensive rearrangements and LOH in allelotyping studies (Carter et al., 1990; Bergerheim et al., 1991; Kunimi et al., 1991) . Later studies narrowed down the LOH target region to the 10q21-25 band (Phillips et al., 1994; Ittman, 1996; Komiya et al., 1996; Lacombe et al., 1996; Trybus et al., 1996; Cappellen et al., 1997) . LOH on 10q also occurs during the onset and progression of a wide variety of human malignancies including renal cell carcinoma (Morita et al., 1991) , glioblastoma (Karlbom et al., 1993) , meningioma (Rempel et al., 1993) , malignant melanoma (Herbst et al., 1994) , and endometrial cancer (Peier et al., 1995) . The gene causing Cowden Disease (CD) is also located on this chromosome arm (Nelen et al., 1996) . This autosomal dominant inherited cancer syndrome is characterized by hamartomas of multiple organs and various other cancers (Albrecht et al., 1992) . The CD gene was initially mapped to a 5 cM region within 10q22-23 by linkage analysis (Liaw et al., 1997) . In subsequent studies, the Cowden critical region was narrowed down to an interval of less than 1 cM (Liaw et al., 1997; Marsh et al., 1997a) , in which a candidate tumor suppressor gene named PTEN/MMAC1/TEP1, located between D10S1765 and D10S541, has identi®ed Li and Sun, 1997; Steck et al., 1997) . Mutational analysis of this gene in CD kindreds, as well as in a related hamartoma syndrome BannayanZonana syndrome, has identi®ed germline mutations (Liaw et al., 1997; Marsh et al., 1997b; Nelen et al., 1997) , suggesting that PTEN is the CD gene and that Bannayan-Zonana syndrome is allelic to CD. PTEN contains nine coding exons and encodes a 403 amino acid protein which is a dual-speci®ty phosphatase (Myers et al., 1997) . Protein tyrosine phosphatases have been shown to act as either positive or negative regulators during signal transduction, cell cycle progression, and cell transformation. Genetic data and the putative function of PTEN both suggest that it is a tumor suppressor gene. The protein also shows homology with tensin, which appears to bind actin ®laments at focal adhesion complexes that contain integrins. Integrins have been implicated in cell growth regulation and tumor cell invasion (Clark and Brugge, 1995) . PTEN might, therefore, play a role in these processes. With the aim of elucidating the role of PTEN in prostate tumorigenesis, we examined the status of this gene in 22 paired tumor and lymphocyte DNAs by using nine polymorphic markers spanning the 10q22-23 region. Six tumors preselected on the basis of LOH in this interval were subsequently analysed for the presence of somatic PTEN mutations.
Results
We analysed prostate tumor DNA and corresponding constitutional DNA from 22 patients with prostate cancer, using nine polymorphic markers mapping to the 10q22-23 region. All patients were informative for four or more markers on 10q. Allelic imbalance (AI) was found at one or more loci in 12 (55%) of the 22 tumor DNAs. The percentage of tumors with AI at each marker is shown in Table 1 . These 12 10q-altered tumors only exhibited partial deletion, at either one or several markers on the long arm of chromosome 10 ( Figure 1) .
In this study, six tumors (T28, T30, T40, T45, T55, T77) showed a deletion in an interval including the PTEN locus, between D10S1765 and D10S541. The other tumors (T21, T27, T46, T47, T52, T59) showed deletions in 10q22-23, but not aecting the PTEN locus.
We found no cases of homozygous deletion of PTEN among the tumors with LOH in the interval containing the gene. We searched mutations of PTEN in ten tumors, including the six tumors showing LOH in the interval containing PTEN. We found one somatic mutation in one tumor showing deletion in the interval containing PTEN (T40). This was as a 1 bp deletion of a C at codon 244, in exon 7, resulting in a frameshift, and leading to a premature termination of the protein at codon 255.
Discussion
We analysed prostate tumor DNA and corresponding constitutional DNA from 22 patients with prostate cancer, using nine polymorphic markers mapping to the 10q22-23 region, including D10S2491, an intragenic marker of PTEN. AI was found in 12 (55%) of the 22 tumor DNAs. Results obtained by means of comparative multiplex PCR supported the notion that all the AIs observed in this study corresponded to LOH. None of the tumors showed LOH at all the informative markers tested, suggesting interstitial deletion rather than loss of the complete arm.
Deletions at chromosome arm 10q have been prominently reported in prostate cancer. The ®rst studies using both restriction fragment length polymorphism and polymorphic repeat marker analysis showed that chromosome 10 exhibited high frequencies of allelic loss, ranging from 30 to 55% (Carter et al., 1990; Bergerheim et al., 1991; Komiya et al., 1996) . These high frequencies of LOH suggest that 10q may contain tumor suppressor gene(s) associated with the development of prostate cancer. The PTEN gene, identi®ed by Li et al. (1997a) and Steck et al. (1997) is a strong candidate for involvement in the pathogenesis of prostate cancer in 10q22-23. In our study, six tumors exhibited allele loss in the interval between D10S1765 and D10S541, wherein lies the PTEN gene. Two other tumors (T27 and T52) showed a deletion in a region more distal than the interval containing PTEN, that could implicate the MXI1 gene, while its involvement in prostate cancer is controversial (Eagle et al., 1995; Gray et al., 1995) . According to Knudson's two-hit hypothesis, tumor suppressor gene function is lost by independent inactivation events of both parental alleles. We detected no case of homozygous deletion among the tumors with LOH in the interval including the PTEN locus, as indicated by no apparent retention at the intragenic marker D10S2491.
We analysed mutations of PTEN in ten tumors, including the six tumors with LOH in the interval encompassing PTEN. We found one somatic mutation in one tumor showing deletion in the interval containing PTEN. Our results in primary prostate cancers mirror those obtained in a subset of other tumor types. While 10q LOH in tumors of the glioneural line, endometrial cancer and malignant melanomas are re¯ected by a frequency of somatic PTEN mutation in both corresponding cell lines as well as primary glioblastomas, endometrial carcinomas and malignant melanomas (Li et Steck et al., 1997) . However, analysis of primary breast carcinomas were disappointing (Rhei et al., 1997) . The PTEN data in thyroid tumors is neither like the glioblastoma/endometrial cancer model nor the breast cancer one; 10q deletion in thyroid tumors is prominent (Dahia et al., in press ). Somatic alteration of PTEN is signi®cantly more frequent in benign thyroid adenomas compared to carcinomas. Our data on prostate tumors lie somewhere in between the three scenarios. Deletion of 10q22-24 loci, including PTEN, appears prominent in prostate cancers.
In our study, we found only one somatic mutation of PTEN, occurred in a hemizygous Gleason grade 8 and stage B prostate carcinoma, in agreement with data from Cairns et al. (1997) on primary localized prostate cancers. Genetic alterations of PTEN are detected in pelvic lymph node metastases (Cairns et al., 1997) , and in various metastatic sites (Suzuki et al., 1998) , suggesting involvement of somatic PTEN alteration in prostate cancer progression.
In conclusion, a high frequency of 10q22-24 deletion was observed in primary prostate cancers, con®rming previous studies. We identi®ed one mutation of PTEN among six tumors showing LOH in the interval spanning the gene. The ®ve other cases were wildtype for PTEN; however, the apparently wild-type allele in hemizygous prostate tumors could be inactivated by other mechanisms, such as hypermethylation leading to gene silence. Additional studies are thus required to determine the possible involvement of PTEN in prostate tumorigenesis.
Materials and methods

Patients and samples
Twenty-two sporadic prostate tumor specimens were obtained from patients undergoing surgery at St Louis Hospital in Paris, and La Cavale Blanche Hospital in Brest (France). The samples were examined histologically to con®rm the presence of tumor cells. A sample was considered suitable for DNA analysis if the proportion of tumor cells was more than 60%. All suitable samples were stored in liquid nitrogen until high-molecular-weight DNA extraction. The histological diagnosis, Gleason score (Mellinger et al., 1967) , and pathologic tumor stage according to the tumor-node-metastasis classi®cation of prostate cancer (Schroder et al., 1992) were determined in each case during a routine clinical workup after surgery. Primary prostate tumor specimens were obtained from 16 clinically localized prostate tumors (nine with disease limited to the prostate and seven with extracapsular extension without seminal vesicles involvement), and from six extended disease (®ve with regional lymph node involvement and one with distant metastases). Peripheral blood lymphocytes were used as a source of normal DNA from each patient.
Detection of microsatellite markers by PCR
We screened the 22 samples with nine microsatellite markers (D10S219, D10S215, D10S1765, D10S2491, D10S541, D10S1735, D10S1739, D10S564, D10S583), mapping to chromosome arm 10q in an interval which spans the PTEN locus (10q22-23). D10S2491 lies within the PTEN gene (Cairns et al., 1997) . The probable order of microsatellite loci was inferred from integrated genetic maps of human chromosome 10 (Dib et al., 1996) (Figure  1 ). Microsatellite markers were assayed by PCR amplification of genomic DNA in the following conditions: ®rst denaturation step for 7 min at 948C, 35 cycles of denaturation for 1 min at 948C, annealing for 1 min at 558C, and extension for 30 s at 728C. A ®nal extension step at 728C was lengthened to 5 min. PCR was performed in a total volume of 50 ml containing 100 ng DNA, 0.6 mM each primer, 0.1 mM each deoxynucleotide triphosphate, 0.5 unit Taq DNA polymerase and 1.5 mM MgCl 2 . Products were diluted 1 ± 3 in denaturing loading buer and heat-denatured, and then 2 ml of each sample was loaded on 6% acrylamide gels containing 7.5 M urea. DNA was then transferred to nylon membranes. CA repeat probes were labeled with 32 P-dCTP by using terminal deoxynucleotidyl transferase. The membrane ®lters were hybridized overnight at 428C with labeled probe, washed, and autoradiographed at 7808C for an appropriate period.
Detection of allelic imbalance
Lymphocyte and tumor DNA from each patient were analysed in adjacent tracks. Allelic Imbalance can only be identi®ed in`informative' cases. Normal DNA samples which were polymorphic at a given locus were considered informative, whereas homozygotes were`uninformative'. The signal intensity of fragments was determined by means of densitometry and/or blind independent scoring by three observers. Although simple PCR ampli®cation cannot be considered as a quantitative assay, we optimized the PCR conditions so that equal amounts of template produced equal amounts of ampli®ed product. Allelic imbalance was considered to be present when the relative intensity of the two alleles in tumor DNA diered from the relative intensity in lymphocyte DNA by a factor of at least 1.5; this latter is a validated cut-o value to determine AI of microsatellite loci in tumor samples containing more than 60% of cancer cells (McGrogan et al., 1994) . Evaluation based on the cut-o of 1.5 agreed well with the results of visual inspection. Each analysis was performed at least twice to ensure reproducible detection of AI (another independent PCR ampli®cation, gel separation, and quanti®cation). In an attempt to distinguish allelic gain from LOH, comparative multiplex PCR (Cairns et al., 1994) was performed with microsatellite marker D4S244 or D21S222 (Hudson et al., 1992) , located in unaltered chromosomal regions (Watanabe et al., 1995) , as internal controls.
Sequencing of PCR products
Mutation analysis of PTEN were performed on the six tumors preselected on the basis of LOH in the interval between D10S1765 and D10S541, which encompasses PTEN. Exons 1 to 9 of the gene were PCR-ampli®ed, and puri®ed using the QIAquick PCR puri®cation kit (Qiagen). The puri®ed fragments were then sequenced using the Applied Biosystems (ABI) PRISM Dye Terminator Cycle Sequencing kit (Perkin Elmer) on the Applied Biosystems model 373A DNA sequencing system (Perkin Elmer). Primers used for PTEN sequencing are presented in Table 2 . 5'-CATAGCAATTTAGTGAAATAACT-3' 3'-GATATGGTTAAGAAAACTGTTC-5' 7 5'-TGACAGTTTGACAGTTAAAGG-3' 3'-GGATATTTCTCCCAATGAAAG-5' 8 5'-CTCAGATTGCCTTATAATAGTC-3' 3'-TCATGTTACTGCTACGTAAAC-5' 9 5'-AAGGCCTCTTAAAAGATCATG-3' 3'-TTTTCATGGTGTTTTATCCCTC-5'
